Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remternetug for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease
NCT06647498Phase 3Recruiting
- Sponsor
- Washington University School of Medicine
- Start
- Nov 2024
- Primary completion
- Mar 2034
- Modality
- Monoclonal Antibodies
- Countries
- 15
01
Overview
A Phase 3 trial of remternetug in Alzheimer's disease (AD), sponsored by Washington University School of Medicine. Started Nov 2024; status: recruiting.
02
Drugs
remternetug
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06647498.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06647498.